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THE EFFECT OF CIGARETTE SMOKING ON SURVIVORS OF A SINGLE 
K’fOCARDIAL INFARCTION 
, James W. Johnson, John P. Matts, Henry 
he POSCH Group. University of Minnesota, 
Hinneapolis. MN 
The effect of smoking on arteriographically documented 
atheroscleroctic coronary heart disease (A-CHD), total 
mortality (TN), atherosekratic coronary heart disease 
mortality (CHD-H), and HI was examined in 334 control 
group patients from the Frogram on the Surgical Control 
of the Hyperlipidemias. The male and female patients 
were between the ages of 30 to 64 years, had elevated 
cholesterol levels, had suffered a single MI and 
included 128 current smokers (CS) and 206 former smokers 
(FS) at entry into the study. At 3,5,7, and 10 years of 
tollow.up, there were no differences in A-CHD 
progression from baseline for CS vs FS as assessed by 
visual readings of the paired coronary arteriograma by 
two cardiologists blinded to the temporal order of the 
films and to the patient’s smoking status. Below is 
shown the relative risk (CS va PS) at up to 10 years of 
follow-up, without and with adjustment for age, HDL- 
end LDL-cholesterol, LV ejection fraction, quetelet 
index, and amount of coronary atherosclerosis at 
baseline, using Cox regression. 
TM CHD-M CHD-H+HI 
CS vs FS 2.4* 2 I 7* 2.0* 
CS vs FS adjusted 2.6* 3.3* 2.4* *mp<.oo3 
: Post-MI patientr who continue to smoke, 
compared to post-HI patients who stop snok:ng, are at 
increased risk of death and recurrent MI. The lack of a 
difference in arteriographically documented coronary 
atherosclerosis progression between tht ;;o groups may 
indicate that other factors such as vasospasm or 
clotting mechanisms are involved. 
2:JS 
SHORT- AND LONGTER 
FICTION 
Francols Ricou, Pascal Nicod, Elizabeth Gilpln, John Ross Jr. 
University of California, San Diego Madioal Center, CA 
In patients with inferior Q-wave myocardlal lnfarctlon (MI), It is 
unclear whether short- and brig-term pqnosls Is Influenced by the 
presence of right bundle branch block (RBBB). We therefore studied 
the ofinioal outcome of pts with IMI without (n:1489) and with RBBB 
(n:lOS). 
Pts with RBBB were older (mean&SD: 67~11 vs 61k12 years), more 
often had a history of previous MI (35 vs 20%) or cardiac failure 
(17 vs 6%), and clinical evidence of left ventricular failure in 
hospital (48 vs 35%, all p<O.Ol). In-hospital and one-year post 
discharge cardiac mortalities In Dts wlth RBBB were 11 and 14% 
compared to 6 and SK in pts without RBBB (respeotfvaly, p<i.& and 
fkO.001). On multivariate analysis, the oresence of RBSB was an 
independent predictor of one-year post bisoharge mortality but- not 
in-hospital mortality. The increased one-year post discharge 
mortality in pts with RBBB compared to patients without RBBB was 
seen both in pts with (19% vs 8.7%; ~0.06) and without (10.2% vs 
2.7% : ~~0.02) clinical left ventricular failure in hospital. Outcomes 
of pts with old RBBB (26% of population) and new or of 
indeterminate age RBBB (75% of oooulatfon) were not different. 
Occurence of complete heart 
- - _. 
in ihe hospital was~no~&nibantly 
different between pts with and without RBEB (15% vs 11%). 
Conclusion: The presence of RBBB folbwing i&for 6wav<Ml: 
1) identifies pts with increased one-year post discharge mortality 
who may benefit from further diagnostic and therapeutic procedures. 
2) is not associated with a significantly higher incidence of oomplete 
heart block In hospital. 
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The Impact of lytic Antiplatelet Therapy 
on Coronsry Heart Disease Mortality. 
Peter L Thompson MD FACC, Michael ST Hobbs MA DPhil, 
Konrad D Jsmrozik MB DPhil, Richard Parsons Ph.D. 
Unit of Clinical Epidemiology Jnd Dept of 
Cardiovascular Medicine, QEII Medical Centre, Perth, 
Australia. 
While the efficscy of thrombolytic and sntiplatelet 
therapy (Rx) has been documented in randomized 
clinical trials, the impact of these therapies in 
improving outcome in clinical practice has not been 
studied. We used data from 2874 cases of acute 
myocardial infarction (AMI) to study the impact of 
these therapies on coronary heart disease (0) 
mortality in the Perth community of million persons 
aged 25-64. From 1984-1988, the use of thrombolytic Rx 
increased from 2% to 22% and antiplatelet Rx from 26% 
to 82% of cases of AYI treated in coronary car-r units 
(CCU). After correction for other determinants of 
outcome by logistic regression analysis, the relative 
risk of O-28 day death for treated patients was 
compared with patients who received neither therapy. 
The relative risk was 0.9 (95% Cl 0.5-1.7) for 
patients treated with thrambolytic Rx (n=453), 0.43 
(0.3-0.6) for antiplatelet Rx (n=1577), and 0.35 
(0.2-0.7) for the combination (n=293). Of the coronary 
deaths in the community, only 33% of deaths in the 
community occurred in hospital and only 53% of the 
hospital deaths occurred in CCU. Thus the maximum 
impact on CRD mortality of antiplatelet and 
thrombolytic Rx was 0.33 x 0.53 x 0.35 = 0.06 or 6%. 
Because of the larger number of pstients treated, 
antiplatelet therapy had greater effect on mortality 
than thrombolytic therapy. 
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DECLINING CORONARY HEART DISEASE MORTALITY AND MORBIDITY 
IN MALMU SWEDEN. 
Ole Hansen, Beqt W. Johansson, Section of Cardiology 
General Hospital , Malmij, Sweden. 
A substantial decline in coronary heart disease (CHD) 
mortality has been observed in several industrialized 
countries, but due to shortcomings in measures of CHD 
morbidity it is still unclear whether the decline in mor- 
tality is due to a decline in morbidity, case fatality, 
or both. In Malmii, a community with a stable and defined 
population of 230,000 inhabitants, completeness in case 
finding and a homogeneous case ascertainment is facili- 
tated by the facts that the whole population is served by 
only one hospital, and that the autopsy rate exceeds 80%. 
A continuous monitoring of myocardial infarction (MI) in- 
cidence since 1935 shows an increasing morbidity until 
the mid-1970s and then a declining trend. The decline in 
morbidity was followed by a decline in mortality 
>70 yr 
Year Men 
60-69 yr 50-59 yr 
Women Men Women Men 
CHD- 
mortal i ty 
1975 3,138 1,829 1,018 256 335 
1986 2,607 1,607 940 240 358 
change % -17 -12 -8 -6 +7 
MI- 1975 1,326 828 779 293 433 
incidence 1986 1.217 672 660 222 411 
change % - -8 -19 
_-- - 
-15 -24 -5 
MI in-hosp. 1975 41 44 24 22 10 
case fatality 1986 
change % -3; -i -:; =-ii 
11 
+to 
It is concluded that in Malmii the decline in CHD mortali- 
ty seen in most age groups is explained partly by a de- 
cline in CHD morbidity, but that also a decline in in- 
hospital case fatality of MI has contributed. 
